Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
Tuberculosis remains a major health threat globally and a more effective vaccine than the current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore-FP1 mucosal vaccine candidate is based on the fusion protein of Ag85B-Acr-HBHA/heparin-binding domain, adsorbed on th...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1246826/full |
| _version_ | 1797662927903260672 |
|---|---|
| author | Andrew D. White Andy C. Tran Laura Sibley Charlotte Sarfas Alexandra L. Morrison Steve Lawrence Mike Dennis Simon Clark Sirine Zadi Faye Lanni Emma Rayner Alastair Copland Peter Hart Gil Reynolds Diogo Matthew J. Paul Miyoung Kim Fergus Gleeson Francisco J. Salguero Mahavir Singh Matthias Stehr Simon M. Cutting Simon M. Cutting Juan I. Basile Martin E. Rottenberg Ann Williams Sally A. Sharpe Rajko Reljic |
| author_facet | Andrew D. White Andy C. Tran Laura Sibley Charlotte Sarfas Alexandra L. Morrison Steve Lawrence Mike Dennis Simon Clark Sirine Zadi Faye Lanni Emma Rayner Alastair Copland Peter Hart Gil Reynolds Diogo Matthew J. Paul Miyoung Kim Fergus Gleeson Francisco J. Salguero Mahavir Singh Matthias Stehr Simon M. Cutting Simon M. Cutting Juan I. Basile Martin E. Rottenberg Ann Williams Sally A. Sharpe Rajko Reljic |
| author_sort | Andrew D. White |
| collection | DOAJ |
| description | Tuberculosis remains a major health threat globally and a more effective vaccine than the current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore-FP1 mucosal vaccine candidate is based on the fusion protein of Ag85B-Acr-HBHA/heparin-binding domain, adsorbed on the surface of inactivated Bacillus subtilis spores. The candidate conferred significant protection against Mycobacterium. tuberculosis challenge in naïve guinea pigs and markedly improved protection in the lungs and spleens of animals primed with BCG. We then immunized rhesus macaques with BCG intradermally, and subsequently boosted with one intradermal and one aerosol dose of Spore-FP1, prior to challenge with low dose aerosolized M. tuberculosis Erdman strain. Following vaccination, animals did not show any adverse reactions and displayed higher antigen specific cellular and antibody immune responses compared to BCG alone but this did not translate into significant improvement in disease pathology or bacterial burden in the organs. |
| first_indexed | 2024-03-11T19:07:13Z |
| format | Article |
| id | doaj.art-5d6971450abd4bfbb64716fb58efad30 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T19:07:13Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5d6971450abd4bfbb64716fb58efad302023-10-10T05:14:58ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-10-011410.3389/fimmu.2023.12468261246826Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primatesAndrew D. White0Andy C. Tran1Laura Sibley2Charlotte Sarfas3Alexandra L. Morrison4Steve Lawrence5Mike Dennis6Simon Clark7Sirine Zadi8Faye Lanni9Emma Rayner10Alastair Copland11Peter Hart12Gil Reynolds Diogo13Matthew J. Paul14Miyoung Kim15Fergus Gleeson16Francisco J. Salguero17Mahavir Singh18Matthias Stehr19Simon M. Cutting20Simon M. Cutting21Juan I. Basile22Martin E. Rottenberg23Ann Williams24Sally A. Sharpe25Rajko Reljic26United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomInstitute for Infection and Immunity, St George’s University of London, London, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomInstitute for Infection and Immunity, St George’s University of London, London, United KingdomInstitute for Infection and Immunity, St George’s University of London, London, United KingdomInstitute for Infection and Immunity, St George’s University of London, London, United KingdomInstitute for Infection and Immunity, St George’s University of London, London, United KingdomInstitute for Infection and Immunity, St George’s University of London, London, United KingdomDepartment of Oncology, The Churchill Hospital, Oxford, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomLionex GmbH, Braunschweig, GermanyLionex GmbH, Braunschweig, GermanySchool of Biological Sciences, Royal Holloway University of London, Surrey, United KingdomSporegen Ltd , London Bioscience Innovation Centre, London, United KingdomDepartment of Microbiology, Tumour and Cell Biology and Centre for Tuberculosis Research, Karolinska Institute, Stockholm, SwedenDepartment of Microbiology, Tumour and Cell Biology and Centre for Tuberculosis Research, Karolinska Institute, Stockholm, SwedenUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, United KingdomInstitute for Infection and Immunity, St George’s University of London, London, United KingdomTuberculosis remains a major health threat globally and a more effective vaccine than the current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore-FP1 mucosal vaccine candidate is based on the fusion protein of Ag85B-Acr-HBHA/heparin-binding domain, adsorbed on the surface of inactivated Bacillus subtilis spores. The candidate conferred significant protection against Mycobacterium. tuberculosis challenge in naïve guinea pigs and markedly improved protection in the lungs and spleens of animals primed with BCG. We then immunized rhesus macaques with BCG intradermally, and subsequently boosted with one intradermal and one aerosol dose of Spore-FP1, prior to challenge with low dose aerosolized M. tuberculosis Erdman strain. Following vaccination, animals did not show any adverse reactions and displayed higher antigen specific cellular and antibody immune responses compared to BCG alone but this did not translate into significant improvement in disease pathology or bacterial burden in the organs.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1246826/fulltuberculosisvaccinelungsnon-human primatesaerosol vaccine |
| spellingShingle | Andrew D. White Andy C. Tran Laura Sibley Charlotte Sarfas Alexandra L. Morrison Steve Lawrence Mike Dennis Simon Clark Sirine Zadi Faye Lanni Emma Rayner Alastair Copland Peter Hart Gil Reynolds Diogo Matthew J. Paul Miyoung Kim Fergus Gleeson Francisco J. Salguero Mahavir Singh Matthias Stehr Simon M. Cutting Simon M. Cutting Juan I. Basile Martin E. Rottenberg Ann Williams Sally A. Sharpe Rajko Reljic Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates Frontiers in Immunology tuberculosis vaccine lungs non-human primates aerosol vaccine |
| title | Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates |
| title_full | Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates |
| title_fullStr | Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates |
| title_full_unstemmed | Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates |
| title_short | Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates |
| title_sort | spore fp1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on bcg conferred protection in non human primates |
| topic | tuberculosis vaccine lungs non-human primates aerosol vaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1246826/full |
| work_keys_str_mv | AT andrewdwhite sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT andyctran sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT laurasibley sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT charlottesarfas sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT alexandralmorrison sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT stevelawrence sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT mikedennis sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT simonclark sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT sirinezadi sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT fayelanni sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT emmarayner sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT alastaircopland sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT peterhart sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT gilreynoldsdiogo sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT matthewjpaul sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT miyoungkim sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT fergusgleeson sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT franciscojsalguero sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT mahavirsingh sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT matthiasstehr sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT simonmcutting sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT simonmcutting sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT juanibasile sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT martinerottenberg sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT annwilliams sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT sallyasharpe sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates AT rajkoreljic sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates |